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Abstract. The use of telemedicine is becoming increasingly popular in assisting with the home management of People with
Dementia (PwD) by offering services to the carers that may enhance their ability to care for their relative for longer. A computer-
ized platform, ALADDIN, was evaluated in its usefulness to reduce carer burden and distress and to improve their quality of life,
in an attempt to delay institutionalization of PwD. ALADDIN offers educational material about dementia to carers and provides
the opportunity to contact other carers and clinicians. ALADDIN also facilitates remote monitoring of the PwD and their carers
by the clinicians to enable speedy delivery of appropriate intervention. The ALADDIN platform was piloted at three European
sites, and used by thirty carers of PwD living in the community (platform group). The platform group and a control group of
thirty PwD and their carers were assessed at baseline, 3 months, and 6 months. The results showed a significant improvement
in the quality of life of the carers in the platform group, with some reduction in carer burden and distress. The platform was
useful in monitoring the patients and facilitating contact with other professionals. Access to and use of the ALADDIN platform
was rated positively by carers and clinicians. The ALADDIN platform’s usefulness and applicability for prolonging the home
management of PwD are discussed.
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INTRODUCTION
Background
The growing prevalence of dementia as a result of the
increase in the aging population [1] has led to concerns
regarding the delivery of care and the rising costs of
it. At present around 60% of people with dementia
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(PwD) live in the community and are looked after by
informal (family) carers [2] and the care of the other
40% that are institutionalized cost the economy around
$315billion per annum worldwide [3]. Although the
care of PwD at home is beneficial for the PwD and the
wider society, it places a great burden on the informal
carer. The informal carers of PwD typically experience
high risks of depression [4–6], early mortality [7], and
social isolation [8], as well as reduced quality of life
(QoL) [9] and employment [8]. As a result, the carer’s
burden, distress, and QoL are some of the main issues
that need to be addressed in the care of PwD at home.
In the face of greater demands on health services,
there is now growing interest in the use of telemedicine
systems for management of dementia at home by offer-
ing a range of services that can be used to support
carers of PwD. Many studies report on the useful-
ness of telemedicine interventions for carers of PwD,
including: non-internet computer based forums [10],
computer automated telephone support systems [11],
computerized systems for accessing information [12],
internet library [13], and internet-based videoconfer-
encing [14]. While the outcomes of these studies are
inconsistent and show that the interventions benefit
some but not all carers, they highlight the potential
of telemedicine interventions.
The current study is a multi-center randomized con-
trolled evaluation of a technology platform specifically
designed for PwD living at home and their carers.
The system is entitled: ‘A technology pLatform for the
Assisted living of Dementia elDerly INdividuals and
their carers’ (ALADDIN).
ALADDIN
ALADDIN is a computerized platform designed to
offer avenues of support and information to the carer.
It also manages and communicates information related
to the PwD and their carers from their home to the clin-
icians, facilitating distant monitoring. ALADDIN has
four key features: ‘ALADDIN TV’, ‘SOCIAL NET-
WORKING’, ‘MY TASKS’, and ‘CONTACT US’.
1) ‘ALADDIN TV’ provides information and edu-
cational material about dementia, as well as
musical entertainment and relaxation and exer-
cise techniques. The provision of information
about dementia online has been shown to be ben-
eficial for carers [15].
2) The ‘SOCIAL NETWORKING’ feature pro-
vides a forum for carers using ALADDIN to
communicate with each other. Contact with other
carers is recommended by NICE guidelines [16].
3) ‘MY TASKS’ is the distant monitoring feature
of ALADDIN, where carers complete question-
naires about their own and their relatives’ health.
Their responses can subsequently generate clin-
ical alerts based on set parameters, comparing
new responses to previous data, resulting in the
immediate detection of change by the clinicians
monitoring the system. This facilitates the speedy
delivery of appropriate interventions to reduce
risks of emergencies and/or institutionalization
in the future.
4) The ‘CONTACT US’ feature allows the carer to
alert the clinical site and/or generate a request for
contact. Such frequent and improved communi-
cation between the carer and health professionals
enhances the carer’s ability to better manage
PwD’s problematic behaviors [17].
Through the distant monitoring of the carers and the
PwD (MY TASKS), provision of pertinent information
about dementia and caring, and access to relaxation
and exercise routines (ALADDIN TV) and avenues of
support (‘CONTACT US’ and ‘SOCIAL NETWORK-
ING’ features), ALADDIN aims to reduce carer burden
and distress and enhance their QoL. Thus the present
study is a randomized controlled evaluation of the
ALADDIN system for continued care of PwD at home.
METHODS
Design
A multi-center randomized controlled pilot study
was undertaken at three European sites: The National
Hospital for Neurology and Neurosurgery (NHNN),
UK; Badalona Serveis Assistencials (BSA), Spain; and
the Psychiatric Hospital of Attica (PHA), Greece. The
study was approved by National Research Ethics Ser-
vice Committee, UK.
Participants
Hospital outpatients identified as having dementia
were screened for functional dependency and cog-
nitive impairment using the Barthel Index (BI) [18]
measure of disability and the Mini-Mental State Exam-
ination (MMSE) [19] measure of cognition. Patients
living at home with a full time carer, a BI score of
at least 35 (indicating some degree of independence),
and a MMSE score of at least 9 and no more than
21 (indicating moderate to mild cognitive impairment)
were recruited. Patients either had dementia as their
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Table 1
Mean and (standard deviation) of demographic and clinical details
of patients in the Platform and Control groups, and p value for the
independent t-test comparisons
Platform Control All p
(n = 30) (n = 30) (N = 60)
Carer
Age 57.57 (12.50) 63.93 (14.74) 60.69 (13.90) 0.079
Patient
Age 78.60 (7.49) 77.47 (6.36) 78.03 (6.91) 0.530
Disease 3.7 (2.48) 2.7 (1.73) 3.2 (2.18) 0.075
duration
BI score 63.5 (22.94) 73.83 (26.35) 68.67 (25.04) 0.111
MMSE score 18.9 (4.55) 19.73 (5.46) 19.32 (5.00) 0.523
Gender 45% male 55% male 55% male 0.201
variation 55% female 45% female 45% female
BI, Barthel Index; MMSE, Mini-Mental State Examination.
primary condition or dementia as part of Parkinson’s
disease. Informed consent was sought from all partic-
ipants (patients and their carers), and an assent form
was signed by the carer if the PwD lacked capacity
to provide consent. The general practitioners of all
patients were informed of their participation in the
study. Twenty participants (patients and their carers)
were recruited at each site. Ten participants from each
site were then randomly allocated to the control group
(n = 30), and ten to the platform group (n = 30). There
were no significant differences in key demographic
variables between the two groups at the time of recruit-
ment (See Table 1).
Procedure
At each pilot site, one clinician and one techni-
cian were involved in the project. The project ran for
6 months, and all participants were assessed in their
homes at three time points: baseline, 3 months, and 6
months. The platform participants were visited prior
to the baseline assessment and provided with access to
the ALADDIN platform to use for the duration of the
study. Internet connection and laptops were provided
where necessary. The carers were trained so that they
could navigate the system and complete ‘MY TASKS’
monitoring of the PwD and their own mental state and
burden. Data from ‘MY TASKS’ were used solely for
the purposes of identifying change during the project
period, and were not used as part of the evaluation of
change in patients or their carers. Being the primary
users of ALADDIN, the carers chose the schedule of
their tasks. The system was monitored twice daily by
the clinical teams. The participants in the control group
were only assessed at the three time points, without any
further contact or intervention.
Measuring instruments
The assessments conducted at baseline, 3 months,
and 6 months on both groups were identical. The
assessments completed with the carers were used for
evaluating the usefulness of ALADDIN to reduce carer
burden and distress and enhance QoL. The assessments
of PwD were used solely for the description of sample
which may have influenced carer outcomes.
Assessments completed with carer
Zarit Burden Interview (Zarit) [20]: a 22 item instru-
ment which measures carer’s perceived burden of
providing care. With a total range of 0–88, higher
scores indicate greater burden.
Neuropsychiatric Inventory (NPI) [21]: this inter-
view schedule with carers is used to measure
occurrence of psychiatric and behavioral problems
in the PwD. It assesses 12 domains: hallucinations,
delusions, agitation/aggression, dysphoria/depression,
anxiety, irritability, disinhibition, euphoria, apathy,
aberrant motor behaviors, sleep, and appetite. The fre-
quency and severity of the behavior in question are
multiplied and added to give the total NPI value, and the
carer’s distress scores are added to give a separate sum.
Beck Depression Inventory (BDI) [22]: a 21 item
scale, measuring somatic, cognitive, affective and
behavioral aspects of depression. With a possible range
of 0–63, scores of 0–9, 10–18, 19–25, and 30+ rep-
resent normal, mild, moderate, and severe depression
respectively.
Zung Depression Self Rating Scale (Zung) [23]: a
20 item questionnaire covering affective, psychologi-
cal, and somatic symptoms of depression. Score range
is 20–80, with higher scores representing more severe
depression. A score above 50 indicates clinical depres-
sion outside the normal range.
EuroQoL (EQ5D) [24]: a 5 item questionnaire cov-
ering five dimensions of QoL: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression.
The sub-scores can be combined to give a summary
index value of 0-1. The EQ5D also includes a visual
analogue scale for rating ‘current health state’. Lower
scores represent poorer QoL for both.
Quality of Life Scale (QOLS) [25]: a 16 item ques-
tionnaire measuring six domains of QoL: material and
physical well-being, relationships with others, social,
community, and civic activities, personal development
and fulfilment, and recreation. With a range of 16–112,
higher scores indicate better QoL.
Due to the European collaborative nature of this
project, and the fact that some scales were not avail-
able or validated in some languages, QoL and mood
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were assessed using different scales. To measure QoL,
QOLS was used by two of the three clinical sites and
EQ5D was used by one. Similarly, to measure carer’s
mood, BDI was used by one site at each assessment,
and Zung was used by two sites at the final assessment
only. Consequently, carers QoL are reported using both
the EQ5D and QOLS, and the cut off points for the
depression scales (Normal, Mild, Moderate, Severe)
were used to make the BDI and Zung depression scales
comparable.
Assessments completed with PwD
The patient’s blood pressure and weight were
recorded on the day of the assessment, and the PwD
were tested on a number of assessment tools including
the following:
Mini-Mental State Examination (MMSE) [19]: a 30
item measure of global cognitive functioning covering:
orientation, memory, language, and executive function.
The score range is 0–30, with higher scores represent-
ing better cognitive functioning. Scores below 24 are
considered to indicate cognitive impairment.
Mattis Dementia Rating Scale 2 (DRS2) [26]: a
36 item test of cognitive function covering: attention,
initiation-perseveration, construction, conceptualiza-
tion, and memory. The score range is 0–144, where
higher scores represent better performance.
Blessed Dementia Rating Scale (BDRS) [27]: a 22
item questionnaire covering: everyday activities, self
care habits, and changes in personality, interests, and
drives. Each item is rated from 0 (total capacity) to 0.5
(intermittent incapacity) to 1 (total incapacity).
Clinical Dementia Rating Scale (CDRS) [28]: a 6
item questionnaire measuring: memory, orientation,
judgment and problem solving, community affairs,
home and hobbies, and personal care. Each item is
scored on a scale of 0 (no impairment) to 3 (severe
impairment). Memory is the main category, and pro-
vided that at least two of the other items have the same
severity score as the memory subtest, that score is con-
sidered to represent the overall CDRS score; otherwise
the score given to the majority of the items becomes
the overall CDRS score.
Revised Memory and Behavior Problems Checklist
(MBPC) [29]: a 24 item questionnaire covering: mem-
ory related problems, affective distress and disruptive
behaviors, and their impact on the carer. With a total
range of 0–96, the higher the score, the more frequent
the problem. The carer’s distress can also be calculated
in the same way.
Geriatric Depression Scale (GDS) [30]: a 15 item
measure of depression. Each answer that is indicative
of depression is given a score of 1. With a total range
of 0–15, scores above 5 indicate depression.
Barthel Index (BI) [18]: a measure of functional dis-
ability looking at independence in activities of daily
living. The items cover: feeding, bathing, grooming,
dressing, bowel control, bladder control, toileting,
chair transfer, ambulation, and stair climbing. The ten
items give a total range of 0–100, with higher scores
representing increasing dependence.
Lawton Activities of Daily Living (LADL) [31]:
a measure of independent living covering function-
ing in 8 domains: ability to use telephone, laundry,
shopping, mode of transportation, food preparation,
responsibility for own medication, housekeeping, and
ability to handle finances. The eight items give a total
range of 0–8, with higher scores showing increasing
independence.
Charlson’s Comorbidity Index (CCI) [32]: a 19 item
index, consisting of a range of morbid conditions. Each
condition has a pre-assigned score depending on risk of
dying associated with it. All scores are added together
to give the predicted value of mortality for the patient.
The higher the score, the higher the predicted mortality.
Evaluation of the ALADDIN platform
In addition to the assessment of carers, to evalu-
ate the ALADDIN platform’s usefulness, two specific
questionnaires looking at the experiences of its main
users were developed. The main users of the plat-
form were the carers who completed the tasks and
navigated the system, and the clinicians who set the
tasks and monitored the system. The carer and clin-
ician ‘satisfaction questionnaires’ consisted of rating
scales measuring the ease of use of the system, the
user’s willingness to continue using it, and recom-
mending it to a friend (carer) or substituting it with
in-person consultations (clinician). The questionnaires
also assessed the carer’s perception of ALADDIN in
enhancing/increasing awareness of their own and their
relative’s wellbeing, and other questions related to the
frequency of the tasks and their toll on increasing
duties. The clinicians were asked about their thoughts
on the automatically generated alerts, the overall value
of ALADDIN and its suitability and potential for the
future management of PwD in their services.
Statistical analyses
A series of independent t-tests and analysis of
covariance (ANCOVA) were conducted using the
SPSS software for Windows (version 20). To evaluate
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Fig. 1. Changes in the quality of life (QoL) and burden measures
for the carers in the Platform and Control groups over the six month
period of study. The mean and standard error of the mean (error bars).
changes across the two groups over time, a repeated
measures Mixed ANCOVA was conducted with Group
(Platform versus Control) and Time of Assessment (3
and 6 months) as the between and within subjects vari-
ables respectively. Scores from the baseline assessment
were used as the covariates.
RESULTS
Carer burden, distress, and quality of life
A series of independent t-tests were carried out
to identify any differences between the carers in the
platform and control groups at baseline. The compar-
isons revealed significant differences in carer burden
[Zarit; t(58) = 2.063, p = 0.044] and QoL [QOLS,
t(58) = −2.286, p = 0.026] (see Table 2), showing
higher burden and worse QoL for carers in the plat-
form group than those in the control group. These
results were used as covariates in subsequent analysis
of variance.
A number of two-way ANCOVAs were conducted
to look at the effect of Group and Time of Assessment,
and any interaction between the two variables, on carer
burden, distress, and QoL.
Although there were no significant differences in rat-
ings of carer burden between the two groups (p > 0.05
for all), to determine the success of ALADDIN in
reducing carer burden, the average change in the rele-
vant measure was calculated (See Fig. 1). This showed
that during the course of the pilot study, on average,
the burden of caring was reduced more in carers in the
platform group (M = −2.2; SD = 13.01) than those in
the control group (M = −0.3; SD = .27).
The results showed no significant main effects or
interactions on the carer’s distress associated with their
Fig. 2. Changes in the quality of life (QoL) of carers in the Platform
and Control groups as measured by EQ5D over the six month period
of study. The mean and standard error of the mean (error bars).
relatives’ neuropsychiatric symptoms (NPI carer dis-
tress ratings) (all p > 0.05).
ANOVA was not possible for depression scores for
all participants due to missing data. Thus we com-
pared the severity of depression at the final assessment,
and although the group differences did not reach sta-
tistical significance [χ2(2,57) = 1.33, p = 0.514], there
were some notable differences. While 75% of the car-
ers in the platform group scored in the normal range
and 25% had mild depression, 66% of carers in the con-
trol group scored in the normal range, 31% had mild
depression, and one had moderate depression (3%).
Furthermore, despite reports of poorer QoL in carers
in the platform group at baseline relative to controls,
a significant Group x Time of Assessment inter-
action was found for the EQ5D measure of QoL
[F(1,16) = 5.9317, p = 0.027)]. This significant interac-
tion was due to the improvement in the QoL of carers in
the platform group at 6 months (see Fig. 2). Since QoL
was measured using QOLS by two of the clinical sites
and EQ5D by one site only, the scores were converted
into percentages to enable comparisons. The average
change in carers’ QoL from baseline to six months
was a 4.1% gain (SD = 14.24) for carers in the plat-
form group, and a 1.2% loss (SD = −7.53) for carers
in the control group (see Fig. 1)
To investigate whether the improvements reported
above were related to the platform carers’ use of
ALADDIN, we looked at their responses from the
carer-satisfaction questionnaire. A large percentage
of the carers felt that ALADDIN: gave them more
confidence because of the frequent monitoring of
their relative (64%); made them more aware of their
relative’s health (53%); and provided them with infor-
mation about dementia (56%). Also while some carers
felt that ALADDIN reduced their anxiety about their
relative’s health (46%), most considered ALADDIN
as having the potential to improve their QoL (60%).
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Change in PwD
A number of independent t-tests were completed to
identify any significant differences at baseline between
PwD in the two groups. The analyses revealed sig-
nificant differences on the patients’ dementia severity
[CDRS; t(58) = 1.837, p = 0.051] and neuropsychiatric
symptoms [NPI; t(57) = 2.129, p = 0.038], showing
higher severity in patients randomly allocated to the
platform group. These group differences remained sig-
nificant at 3 and 6 months (all p < 0.05).
In addition, a series of two-way ANCOVAs
were conducted to identify any changes between
PwD in the platform and control groups over
time. There were no significant interactions, how-
ever the results showed significant main effects for
Group on the MMSE [F(1,52) = 7.189, p = 0.010] and
CDR [F(1,54) = 4.600, p = 0.036] scores, and for the
patient’s weight [F(1,34) = 7.4470, p = 0.010]. Inspec-
tion of the means indicate poorer outcomes in patients
in the platform group on the MMSE and CDR (see
Fig. 3a, b) scores. On the other hand, however, the
patients in the platform group showed a weight gain
(see Fig. 3c). No other significant interactions or main
effects were observed.
DISCUSSION
The aim of this study was to investigate whether
access to information and support through a
telemedicine system, and frequent monitoring of PwD
and their carer, could help reduce carer burden and dis-
tress and improve the carer’s QoL. In comparison to a
control group, the results showed some reduction in
carer burden and distress and improvement in the QoL
of carers that were given access to the computerized
platform ALADDIN.
Despite the random allocation, the participants in the
platform group showed poorer outcomes at baseline
relative to the controls. However a key theme emerg-
ing from our findings is that despite the variance at
baseline, during the course of the study period or at
the final assessment, the participants in the platform
group showed greater improvements relative to the
controls.
In line with previous studies looking at the effec-
tiveness of telemedicine interventions in reducing carer
burden [12–14], we did not find any statistically signif-
icant results for carer burden. However we did observe
a greater reduction of burden during the course of
the study in carers using ALADDIN relative to the
controls, and the carers’ overall response to using
Fig. 3. Changes in the average scores of the patients in the Platform
and Control groups on the MMSE (a) and CDR (b), and their weight
(c) over the six month period of the study. The mean and standard
error of the mean (Error bars).
ALADDIN was also positive. Thus, continued use of
the system may have introduced significant results.
Furthermore, contrary to previous studies which
have shown improvements in self-efficacy and confi-
dence [13], but not depression [11, 12] in carers using
telemedicine interventions, in our sample the carers
in the platform group showed slightly milder forms
of depression than those in the control group at the
final assessment. Although due to missing data we
were unable to determine if this difference existed at
baseline, feedback from the carers using ALADDIN
suggested that the provision of information and the
frequent monitoring of their relative with dementia
through ALADDIN reduced their anxieties and gave
them more confidence.
In addition, our results showed a significant interac-
tion on carer QoL. Inspection of the means indicate
that despite lower QoL at baseline in the platform
group, 6 months after the use of ALADDIN they had
higher self-reported QoL than those in the control
group. Figure 2 illustrates a non-parallel pattern in
these scores, indicating that although there is a small
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drop in QoL for both groups at 3 months (greater in the
platform group), there is a sharp increase in QoL of the
platform group at six months, whereas those in the
control group show a further drop in QoL. This is
a probable illustration of the pattern of change in
QoL that could be expected following increased use
of ALADDIN, however in the absence of additional
follow-up data at a later time point, it is difficult to
comment on this. Similarly, since this significance was
only found for a third of the sample that had rated their
QoL on the EQ5D, this significant interaction should be
interpreted with caution. Nonetheless, when we con-
verted the QoL scores into percentages to make the
outcome scores comparable across the three pilot sites,
we found favorable results. These subsequent results
showed that over the course of the pilot study, on aver-
age there was an improvement in the QoL of carers
using ALADDIN, while there was a small deterioration
in the QoL of the carers in the control group. Similarly
feedback from the carers using ALADDIN suggested
that they considered the system to have the potential to
enhance their QoL.
In monitoring the PwD, the results showed a sig-
nificant weight gain in patients in the platform group
despite their significantly lower weight relative to
control group at baseline. Older patients with demen-
tia and particularly those with dementia as part of
Parkinson’s disease experience dysphagia (swallow-
ing difficulties), have poor diets, and can experience
weight loss [33, 34]. Although presence of dyspha-
gia was not formally assessed in this study, during the
study period, the eating habits of the patients in the
platform group were monitored through ALADDIN
via the set questionnaires (‘MY TASKS’), and referrals
to dietary specialists were made when a problem was
detected. This provides a possible explanation for the
significant weight gain in the platform group. Hence
frequent monitoring of patients was useful in providing
key clinical data for improving the management of the
PwD’s care, including facilitating referrals and contact
with other health professionals when necessary.
Although our results show statistically modest
results, partly because of the small sample size, the
relatively short duration of the pilot study, and the
inconsistent assessment tools used for measuring QoL
and depression in carers across the three pilot sites
which restricted certain analyses; the results show
promising trends that need to be further explored.
Since the use of ALADDIN was an active interven-
tion, the inclusion of a sham treatment in the control
group was difficult. It can be argued that in the absence
of a placebo group the improvements observed in
the platform group may reflect their experience of
the placebo effect. Although this would threaten the
validity of the benefits of ALADDIN as shown by
the results, its relevance is limited. The purpose of
ALADDIN is to alleviate feelings of burden and dis-
tress in carers of PwD. Thus the perceived or actual
improvements observed in carers in the platform group
relative to those in the control group illustrate that the
use of ALADDIN does create a ‘sense’ of support
which can be beneficial for the carers. The results also
indicate that ALADDIN which brings together three
distinct elements of support, information, and frequent
monitoring, has the potential to reduce carer distress
and burden and to improve QoL. Moreover our results
highlight the importance of qualitative information in
providing insight into some of the findings which may
not reflect the true effects of an intervention due to time
and resource constraints.
The application of telemedicine such as the
ALADDIN platform can be easily implemented into
existing personal computers and laptops, but requires
further robust demonstration of its application and
cost-efficacy in routine dementia care which remains a
task for future studies. Future studies are encouraged to
closely match the control and the experimental groups
at baseline, as equivalence of groups at baseline may
help to more clearly demonstrate the usefulness of a
telemedicine system such as ALADDIN. Nonetheless,
this study offers a randomized controlled evaluation of
ALADDIN and establishes its merits.
ALADDIN is a platform that allows great flexibility
and that can be tailored to individual cases and altered
as changes in dementia dictate/necessitate over time.
It offers convenient access from home, reducing the
need to travel, which can be particularly useful for
patients living in remote locations or those with physi-
cal restrictions. It also has the potential to reduce wider
healthcare costs, such as the need for clinical resources
and time to see patients, and can reduce waiting times
and address needs quickly and more effectively. Thus,
ALADDIN can be useful in not only supporting the
carers of PwD and prolonging their care at home, but
also in contributing to the better management of their
care.
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